Compared to the CT26 + IR group, the CT26 + IR + Enbrel group showed a 2-fold lower total tumor volume (120.5 ± 18.7 mm3 vs. 58.7 ± 15.5 mm3), and a 2-fold lower tumor number (15.3 ± 2.5 vs. 7.7 ± 1.5) (Figure 2B, C). The gene discussed is DDX53; the disease is neoplasm.